On May 25, 2021 Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, reported Scott Hutton, Chief Executive Officer of Biodesix, will present at the William Blair 41st Annual Growth Stock Conference being held virtually June 1-3, 2021 (Press release, Biodesix, MAY 25, 2021, View Source [SID1234580569]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

William Blair 41st Annual Growth Stock Conference
Date: Wednesday, June 2, 2021
Time: 2:00 PM CT

The presentation will be webcast live and available for replay under "News & Events" in the Investors section of the Company’s website at www.biodesix.com.

On May 25, 2021 Blueprint Medicines Corporation (NASDAQ: BPMC) reported its participation in the following upcoming investor conferences (Press release, Blueprint Medicines, MAY 25, 2021, View Source [SID1234580568]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:30 p.m. ET.
Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021 at 8:50 a.m. ET.
JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 1:00 p.m. ET.
A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines’ website at View Source A replay of the webcasts will be archived on Blueprint Medicines’ website for 30 days following each presentation.

On May 25, 2021 Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, reported that the Company will present at the 2021 Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 4:00 p.m. ET (Press release, Verastem, MAY 25, 2021, View Source [SID1234580567]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 30 days.

On May 25, 2021 Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, reported a publication in Nature Cancer that gives new insight into the mechanism of long-term durability of effect in acute lymphoblastic leukemia (ALL) patients treated with AUTO1 (Press release, Autolus, MAY 25, 2021, View Source [SID1234580566]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AUTO1 CAR T cells from pediatric ALL patients who still had CAR T cells detectable in the blood more than two years after their treatment were compared with patients who had lost their AUTO1 CAR T cells one to two months post treatment. The study shows that a subset of AUTO1 CAR T cells called Stem Cell Memory T-cells (TSCM) appear critical in both the initial anti-leukemic response and for long term immune surveillance. This suggests that this sub-group of AUTO1 CAR T cells contribute to the long-term durability of effect that AUTO1 has in these patients.

"AUTO1 has been designed to have an optimized interaction between its chimeric antigen receptor and the CD19 target on cancer cells," said Dr Martin Pule, Founder and Chief Scientific Officer of Autolus. "This means AUTO1 can efficiently deliver a kill and disengage rapidly like a normal T cell, leading to less exhaustion and less T cell differentiation. This unique property of AUTO1 potentially contributes to the enrichment and maintenance of this stem cell memory subset that appears to be critical to the long-term durability observed in pediatric ALL patients treated with AUTO1."

On May 25, 2021 United Therapeutics Corporation (Nasdaq: UTHR) reported that Mr. James Edgemond, Chief Financial Officer and Treasurer of United Therapeutics, will provide an overview and update on the company’s business during a fireside chat session at the Jefferies Virtual Healthcare Conference (Press release, United Therapeutics, MAY 25, 2021, View Source [SID1234580565]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The session will take place virtually on Tuesday, June 1, 2021, from 3:30 p.m. to 3:55 p.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at View Source An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed at the same location for 90 days.